Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19323472 | 0.97 | PRCP (0.55) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL15368458 | 0.86 | CYP3A4 (0.52) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL16737242 | 0.86 | CYP3A4 (0.52) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL9980252 | 0.86 | PRCP (0.50) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL749667 | 0.85 | PRCP (0.50) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL16499294 | 0.85 | PRCP (0.50) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL19324250 | 0.85 | PRCP (0.49) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL15405447 | 0.84 | PRCP (0.51) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL18870546 | 0.84 | USP30 (0.46) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL19324237 | 0.84 | PRCP (0.41) | PRCPCYP3A4CYP2C9KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | PRCP 107/4885CYP3A4 177/4885CYP2C9 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.